The chemokine receptor 5 Δ32 mutation is associated with increased renal survival in patients with IgA nephropathy

Kidney International

Volumn 67, Issue 1, 2005, Pages 75-81

  Panzer, Ulf ^b   Schneider, André ^b   Steinmetz, Oliver M ^b   Wenzel, Ulrich ^b   Barth, Petra ^b   Reinking, Rüdiger ^b   Becker, Jan U ^b   Harendza, Sigrid ^b   Zahner, Gunther ^b   Fischereder, Michael ^b   Krämer, Bernhard H ^b   Schlöndorff, Detlef ^b   Ostendorf, Tammo ^b   Floege, Jürgen ^b   Helmchen, Udo ^b   Stahl, Rolf A K ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b NONE

Author keywords

Chemokine; Glomerulonephritis; Monocyte; RANTES

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR 5; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CCR5 GENE; CHEMOTAXIS; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN A NEPHROPATHY; IN VITRO STUDY; KIDNEY BIOPSY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OUTCOMES RESEARCH; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANK SUM TEST; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SURVIVAL;

EID: 19944410138     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00057.x     Document Type: Article

References (28)

1. CATTEL V: Macrophages in acute glomerular inflammation. Kidney Int 45:945-952, 1994
2. HOLDSWORTH SR, KITCHING R, TIPPING PG: Th1 and Th2 T helper subset affect patterns of injury and outcome in glomerulonephritis. Kidney Int 55:1198-1216, 1999
3. DONADIO JV, GRANDE JP: Medical progress: IgA nephropathy. N Engl J Med 347:738-748, 2002
4. FLOEGE J, FEEHALLY J: IgA nephropathy: Recent developments. J Am Soc Nephrol 11:2395-2403, 2000
5. D'AMICO G: Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. Am J Kidney Dis 36:227-237, 2000
6. FALK MC, NG G, ZHANG GY, et al: Infiltration of the kidney by alpha beta and gamma T cells: Effects on progression in IgA nephropathy. Kidney Int 47:177-185, 1995
7. ALEXOPOULOS E, SERON D, HARTLEY RB, et al: The role of the interstitial infiltrates in IgA nephropathy: A study with monoclonal antibodies. Nephrol Dial Transplant 4:187-195, 1989
8. LI HL, HANCOCK WW, HOOKE DH, et al: Mononuclear cell activation and decreased renal function in IgA nephropathy with crescents. Kidney Int 37:1552-1556, 1990
9. BAGGIOLINI M: Chemokines and leukocyte traffic. Nature 392:565-568, 1998
10. ROT A, VON ANDRIAN UH: Chemokines in innate and adaptive host defense: Basic chemokinese grammar for immune cells. Annu Rev Immunol 22:1-29, 2004
11. PANZER U, SCHNEIDER A, WILKEN J, et al: The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis. Kidney Int 56:2107-2115, 1999
12. SEGERER S, MACK M, REGELE H, et al: Expression of the C-C chemokine receptor 5 in human kidney diseases. Kidney Int 56:52-64, 1999
13. LIBERT F, COCHAUX P, BECKMAN G, et al: The delta CCR5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet 7:399-406, 1998
14. SAMSON M, LIBERT F, DORANZ BJ, et al: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 383:722-725, 1996
15. LIU R, PAXTON WA, CHOE S, et al: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377, 1996
16. DEAN M, CARRINGTON M, WINKLER C, et al: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856-1862, 1996
17. HALL IP, WHAETLY A, CHRISTIE G, et al: Association of CCR delta 32 with reduced risk of asthma. Lancet 354:1264-1265, 1999
18. ZAPICO I, GOTO E, RODRIGUEZ A, et al: CCR-5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immunol 1:288-289, 2000
19. FISCHEREDER M, LUCKOW B, HOCHER B, et al: Prolongation of renal transplant in patients lacking a functional CC chemokine receptor-5 (CCR-5). Lancet 357:1758-1761, 2001
20. EUROPEAN RENAL ASSOCIATION-EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION: Section I. Measurement of renalfunction, when to refer and when to start dialysis. Nephrol Dial Transplant 17 (Suppl 7):7-15, 2002
21. PANZER U, THAISS F, BARTH P, et al: MCP-1 and osteopontin differentially regulate glomerular and tubulointerstitial monocyte recruitment in experimental glomerulonephritis. Kidney Int 59:1762-1769, 2001
22. BARTOSIK LP, LAJOIE G, SUGAR L, CATTRAN DC: Predicting progression in IgA nephropathy. Am J Kidney Dis 38:728-735, 2001
23. I-HONG HSU S, RAMIREZ SB, WINN MP, et al: Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int 57:1818-1835, 2000
24. FENG L, CHEN S, GARCIA GE, et al: Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1. Kidney Int 56:612-620, 1999
25. WADA T, FURUICHI K, SEGAWA-TAKAEDA C, et al: MIP-1α and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 56:995-1003, 1999
26. LIM CS, ZHENG S, KIM YS, et al: Th1/Th2 predominance and proinflammatory cytokines determine the clinicopathological severity of IgA nephropathy. Nephrol Dial Transplant 16:269-275, 2001
27. WU L, PAXTON WA, KASSAM N, et al: CCR5 levels and expression pattern correlate with infectability by macrophage-trophic HIV-1, in vitro. J Exp Med 185:1681-1691, 1997
28. O'BRIEN SJ, MOORE JP: The effects of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 177:99-111, 2000